Crinetics Pharmaceuticals, Inc. filed a current report on September 1, 2026, disclosing the completion of its merger with Vertex Pharmaceuticals Incorporated, under which Crinetics became a wholly owned subsidiary of Vertex at a cash price of $85.00 per share.
Key Highlights
- Merger closed September 1, 2026: Clark Merger Sub, Inc., a wholly owned subsidiary of Vertex Pharmaceuticals Incorporated, merged with and into Crinetics Pharmaceuticals, with Crinetics continuing as the surviving corporation.
- Cash consideration of $85.00 per share: Each share of Crinetics common stock (par value $0.001) outstanding immediately prior to the Effective Time was canceled and converted into the right to receive $85.00 in cash, without interest, subject to applicable withholding taxes.
- Aggregate deal value approximately $10.0 billion: According to the filing, Vertex funded the acquisition using a combination of cash on hand and borrowings under its term loan credit agreement.
- Full vesting of equity awards at closing: All outstanding unvested stock options and unvested restricted stock units became fully vested immediately prior to the Effective Time.
- Trading in Crinetics common stock suspended: The company requested that Nasdaq suspend trading in its common stock effective prior to the opening of trading on the Closing Date, and initiated the process to delist and deregister its shares.
- Entire board of directors resigned: All eight directors, including R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D., and Wendell Wierenga, Ph.D., resigned at the Effective Time.
Crinetics Pharmaceuticals Completes Merger with Vertex, Ending Independent Listing on Nasdaq
According to the filing, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a Delaware corporation headquartered in San Diego, California, completed its acquisition by Vertex Pharmaceuticals Incorporated on September 1, 2026. The merger was carried out through Clark Merger Sub, Inc., a wholly owned Vertex subsidiary, which merged into Crinetics, leaving Crinetics as the surviving corporation and a wholly owned subsidiary of Vertex. The Merger Agreement governing this transaction had been previously disclosed in a filing dated July 6, 2026.
The filing disclosed that each share of Crinetics common stock outstanding immediately prior to the Effective Time was canceled and converted into the right to receive $85.00 per share in cash, without interest and subject to applicable withholding taxes. Stock options with a per share exercise price below $85.00 were canceled and converted into the right to receive the difference between $85.00 and the applicable exercise price, less withholding taxes. Restricted stock units were canceled and converted into the right to receive $85.00 per underlying share, less withholding taxes. Any stock option with a per share exercise price equal to or greater than $85.00 was canceled for no consideration. The aggregate consideration paid by Vertex in connection with the merger was reported as approximately $10.0 billion.
In connection with the merger's completion, the company disclosed the termination of several agreements and plans, including the Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan, the Sales Agreement dated June 21, 2024 with SVB Leerink LLC and Cantor Fitzgerald and Co., the 2018 Incentive Award Plan, the 2015 Stock Incentive Plan, and the 2021 Employment Inducement Incentive Award Plan. The company also notified Nasdaq of the merger's completion and requested that Nasdaq initiate the process to delist the common stock, with a further filing on Form 15 intended to terminate registration and suspend reporting obligations under Sections 13 and 15(d) of the Exchange Act.
What Was Disclosed
The filing reported the September 1, 2026 closing of Crinetics Pharmaceuticals' acquisition by Vertex Pharmaceuticals at $85.00 per share in cash, totaling approximately $10.0 billion, the resignation of all eight directors, termination of equity plans, and initiation of delisting from Nasdaq.




Please wait processing your request...